Raymond Kreienkamp, MD, PhD
Attending in Endocrinology
Boston Children’s Hospital
Featured in the Session: Using Genetics to Elucidate Atypical Diabetes
When
Saturday, June 6
at 8:00 a.m.
Where
R05 (Level 2)
Ernest N. Morial Convention Center
What is your presentation about?
The Rare and Atypical Diabetes Network (RADIANT) is the largest and most comprehensively phenotyped cohort of individuals with atypical diabetes. Using genetic data from individuals in RADIANT, we computed previously established diabetes polygenic scores to determine if polygenic scores could predict phenotypic features in individuals with atypical diabetes. Interestingly, we found that diabetes polygenic scores could predict C-peptide secretion during an oral glucose tolerance test and need for both basal and bolus insulin. Diabetes polygenic scores, thus, may be a helpful prognostic tool for clinicians treating individuals with atypical diabetes.
How do you hope your presentation will impact diabetes research or care?
Individuals with atypical forms of diabetes can be challenging for clinicians to treat. Our research supports the possible role of diabetes polygenic scores in cases of atypical diabetes to provide additional prognostic information to improve diabetes care.
How did you become involved with this area of diabetes research or care?
I have been fascinated by the genetic drivers of diabetes, and how we might be able to use genetics to improve the care of individuals with diabetes. I think there is much to learn in this area, and I have been honored to work with amazing colleagues in the RADIANT study and in Boston.